Latest Strategic Pivot News

Antilles Gold progresses its Cuban joint venture projects, unveiling updated resource estimates and feasibility studies for Nueva Sabana, while expanding La Demajagua’s scope and pursuing financing options.

Rare Foods Australia has secured shareholder approval to voluntarily delist from the ASX, while implementing significant cost reductions and achieving record growth in its Subsea Estate wine brand.

HITIQ Limited is pivoting towards grassroots athletes with its upcoming PROTEQT concussion management system, backed by strategic partnerships and fresh funding. The company aims for a cashflow positive future as it prepares for commercial rollout.

Avenira Limited is advancing its Wonarah Phosphate Project with site mobilisation planned for mid-2025, backed by a $7.567 million capital injection from major shareholder Sichuan Hebang Technology. Operational milestones and regulatory approvals are progressing, positioning the company for first ore shipment in Q4.

Pioneer Lithium Ltd has bolstered its uranium portfolio with acquisitions in Colorado and Namibia, confirmed significant mineralisation, and secured $1.62 million to fund exploration under new CEO Michael Beven.

Audio Pixels Holdings Limited reports significant progress in its MEMS fabrication and ASIC development, targeting wafer completion by Q2 2025 while managing funding and ASX suspension challenges.

Southern Hemisphere Mining has extended the strike of its Cerro-Ferro copper system by 15% to 2.2km and confirmed strong geophysical correlations at Llahuin, setting the stage for deep drilling to test new targets.

ReNu Energy has completed the sale of its hydrogen division and is set to acquire Janus Electric, a pioneer in electric truck battery swapping, backed by a substantial capital raise to scale operations.

DMC Mining progresses its strategic acquisition of the Firawa and Labé uranium projects in Guinea, despite ongoing delays in exploration licence grants. The company extends its capital raising timetable while navigating ASX suspension and financial constraints.

1414 Degrees Ltd advances its transformation into a full-service decarbonised energy provider, delivering key technology and commercial milestones in Q3 FY25 while maintaining a stable cash position.

Vectus Biosystems advances its lead fibrosis drug VB0004 with validated Phase I safety data and strategic cost reductions, while actively pursuing licensing partnerships in China.

Genetic Signatures Ltd reported a robust 71% jump in quarterly sales to $2.9 million, fueled by strong respiratory testing demand in Australia and key US commercial contracts. The company is advancing its automation and instrument customisation strategy to streamline molecular diagnostics offerings.